Barclays Lowers Medpace (NASDAQ:MEDP) Price Target to $500.00

Medpace (NASDAQ:MEDP) had its target price reduced by stock analysts at Barclays from $525.00 to $500.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “underweight” rating on the stock. Barclays‘s target price would suggest a potential upside of 20.18% from the company’s current price.

Other analysts also recently issued reports about the stock. Robert W. Baird raised shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 target price for the company in a research report on Tuesday. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research note on Wednesday, January 28th. Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Mizuho set a $660.00 target price on Medpace in a report on Friday, January 9th. Finally, BMO Capital Markets set a $460.00 price target on Medpace in a research note on Wednesday. Three investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $477.36.

Medpace Trading Down 1.9%

MEDP opened at $416.04 on Wednesday. The stock has a fifty day moving average price of $569.92 and a 200 day moving average price of $537.90. Medpace has a 1 year low of $250.05 and a 1 year high of $628.92. The stock has a market cap of $11.81 billion, a price-to-earnings ratio of 27.19, a PEG ratio of 1.37 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business’s quarterly revenue was up 32.0% on a year-over-year basis. During the same period last year, the business earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts forecast that Medpace will post 12.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Medpace

In other news, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the transaction, the vice president directly owned 27,500 shares in the company, valued at approximately $16,751,625. The trade was a 42.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 668 shares of the business’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total value of $394,580.92. Following the transaction, the chief executive officer directly owned 646,184 shares of the company’s stock, valued at $381,694,426.96. This represents a 0.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 270,533 shares of company stock worth $163,122,826 over the last ninety days. Company insiders own 20.30% of the company’s stock.

Hedge Funds Weigh In On Medpace

Large investors have recently bought and sold shares of the stock. AQR Capital Management LLC boosted its holdings in Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares during the period. Norges Bank acquired a new position in shares of Medpace during the second quarter valued at about $66,597,000. Arrowstreet Capital Limited Partnership lifted its stake in shares of Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after buying an additional 211,411 shares during the period. Franklin Resources Inc. grew its position in Medpace by 158.6% during the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after buying an additional 183,645 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in Medpace by 92.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock worth $194,920,000 after buying an additional 166,654 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.